Health & Fitness
Health and Fitness
Health and Fitness
Wed, August 11, 2010
[ Wed, Aug 11th 2010
] - Market Wire
[ Wed, Aug 11th 2010
] - Market Wire
[ Wed, Aug 11th 2010
] - Market Wire
Tue, August 10, 2010
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
[ Tue, Aug 10th 2010
] - Market Wire
YM BioSciences granted Orphan Drug Designation for CYT387
- Potent, oral JAK1/2 inhibitor - Excellent selectivity against a panel of over 150 structurally diverse protein kinases - Favorable preclinical safety profile - Direct preclinical comparison with other JAK2 inhibitors indicates that very few of the other compounds in development match the potency and selectivity of CYT387.
Contributing Sources
